Clinical Features and Analysis in Pituitary Stalk Interruption Syndrome

Table 2

Endocrine features in 24 PSIS patients.

Parameters	Results	Normal range
IGF-1<-2 SDS, n (%)	24 (100%)
Growth hormone stimulation test: growth hormone peak value <5 ng/mL, n (%)	24 (100%)
Growth hormone deficiency, n (%)	24 (100%)
Testosterone (ng/mL)		Male 1.58–8.77
		Female (follicular phase) 0.13–1.30
Estradiol (pg/mL)		Male<44
		Female (follicular phase) 27–122
FSH (IU/L)	0.84 ± 1.14	Male 1–8
		Female (follicular phase) 3.85–8.78
LH (IU/L)	0.31 ± 0.81	Male 2–12
		Female (follicular phase) 2.12-10.89
PRL (ng/mL)	13.68 ± 8.58	Male 1.61-18.77, female 3.34-26.72
Hypogonadism, n (%)	24 (100%)
8:00 am serum cortisol (μg/dL)	2.44 ± 2.64	2.9–19.4
ACTH (pmol/L)	4.36 ± 2.29	0-10.2
24-h UFC (μg/dL)		0.8–11.7
Hypoadrenocorticism, n (%)	22 (91.2%)
FT3 (pmol/L)	4.34 ± 0.85	2.63–5.7
FT4 (pmol/L)	6.82 ± 2.18	7.5–21
TSH (mIU/L)	3.74 ± 1.71	0.3–5.95
Hypothyroidism, n (%)	21 (87.5%)
Urine specific gravity	1.015 ± 0.006	1.005–1.030
Diabetes insipidus, n (%)	0 (0%)
With 4 hormone deficiencies, n (%)	20 (83.3%)
With 3 hormone deficiencies, n (%)	3 (12.5%)
With 2 hormone deficiencies, n (%)	1 (4.2%)

Below detection value. Data are expressed as mean ± standard deviation and numbers (percentage). IGF-1, insulin-like growth factor-1; SDS: standard deviation score; FSH, follicle stimulating hormone; LH, luteinizing hormone; PRL, prolactin; ACTH, adrenocorticotropic hormone; 24-h UFC, 24-h urinary free cortisol; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone.